ClinicalTrials.gg
CompletedNCT02392507Updated Nov 19, 2020Results posted

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

A Phase 2 interventional study of Necitumumab and Nab-Paclitaxel in Carcinoma, Non-Small Cell Lung Cancer (NSCLC), sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-19.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Enrollment
155th of 358
54 · median 48
Started
2015
with 12 others
Phase 2
117 of 402
25 open now
Registered
197th of 402
by date
Lead sponsor
6 of 402
Eli Lilly and Company

Among the 402 studies in Carcinoma with a site in United States, this one is the 155th largest by enrollment of the 358 interventional ones that give a count, is one of 13 that started in 2015, is one of 117 in phase 2, and was the 197th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.

03

Conditions studied

  • Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have or cytologically confirmed squamous NSCLC.
  • Have stage IV disease at the time of study entry (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition).
  • Have at the time of study enrollment as defined by , version 1.1 (RECIST 1.1).
  • Have tumor tissue available for biomarker analysis.
  • Have an (ECOG) performance status of 0 to 1.
  • Have adequate organ functions.

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in another clinical trial.
  • Have received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or VEGF receptor.
  • Have received previous chemotherapy for advanced NSCLC. Participants who have received or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry.
  • Have undergone major surgery or received any therapy in the 4 weeks prior to study entry.
  • Have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.
  • Have symptomatic central nervous system (CNS) or (screening not required).
  • Have a history of arterial or venous embolism within 6 months prior to study entry.
  • Have clinical evidence of concomitant infectious conditions.
  • Have a known allergy / history of reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other to one of the administered treatments.
  • Are pregnant or breastfeeding.
  • Have a known history of drug abuse.
  • Have a concurrent active malignancy. Participants with a history of malignancy are eligible provided the participant has been disease-free for ≥3 years, with the following exception: Participants with adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the judgment of the investigator and Lilly clinical research physician/designee may not affect the interpretation of results (for example, prostate, bladder) are eligible.
  • Have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Necitumumab + Nab-Paclitaxel + Carboplatin

    Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg\*min/mL) on day 1 of each cycle, for a maximum of 4 cycles. Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles). Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Necitumumab · Drug: Nab-Paclitaxel · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: From Date of Randomization to Objective Disease Progression (Up to 18 Months)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS defined as time from date of randomization until first radiographic documentation of measured PD defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 mm,or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization,regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis,the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.

    Time frame: From Date of Randomization to Measured Progressive Disease or Death Due to Any Cause (Up to 18 Months)

  2. Overall Survival (OS)

    OS defined as the time from the date of randomization to the date of death due to any cause. Participants who are alive at the time of study completion or are lost to follow-up will be censored at the time they were last known to be alive.

    Time frame: From Date of Randomization until Death Due to Any Cause (Up to 18 Months)

  3. Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])

    Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: From Date of Randomization to Objective Disease Progression or Start of New Anticancer Therapy (Up to 18 Months)

  4. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin

    The Cmin is the minimum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.

    Time frame: Cycle 3 and cycle 4: predose

  5. PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin

    The Cmax is the maximum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.

    Time frame: Cycle 1, 3 and 4: predose and <15minutes (min) post end-of-infusion

  6. Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab

    A participant was considered to have an anti-drug antibody response if anti-drug antibodies (ADA) were detected at any time point.

    Time frame: Predose Cycle 1 Through Short Term Follow Up (Up To 18 Months)

07

Results

Posted Feb 12, 2019

Participant flow

Induction Regimen
Participant flow — Induction Regimen
MilestoneNecitumumab + Nab-Paclitaxel + Carboplatin
Started54
Received at least 1 dose of study drug54
Completed47
Not completed7
Withdrew: Death3
Withdrew: On study treatment at study conclusion1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject2
Maintenance Regimen
Participant flow — Maintenance Regimen
MilestoneNecitumumab + Nab-Paclitaxel + Carboplatin
Started34
Completed32
Not completed2
Withdrew: Death1
Withdrew: On study treatment at study conclusion1

Outcome measures

PrimaryPercentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of nontarget lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
From Date of Randomization to Objective Disease Progression (Up to 18 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])
percentage of participantsNecitumumab + Nab-Paclitaxel + Carboplatin
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])51.0
SecondaryProgression Free Survival (PFS)

PFS defined as time from date of randomization until first radiographic documentation of measured PD defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. PD was at least 20% increase in sum of diameters of target lesions with reference being smallest sum on study and an absolute increase of at least 5 mm,or unequivocal progression of non-target lesions,or 1 or more new lesions.If participant does not have complete baseline disease assessment,PFS time censored at date of randomization,regardless of whether or not objectively determined disease progression or death observed for participant.If participant was not known to have died or have objective progression as of data inclusion cutoff date for analysis,the PFS time censored at last adequate tumor assessment date.The use of new anticancer therapy prior to occurrence of PD resulted in censoring at the date of last radiographic assessment prior to initiation of new therapy.

Time frame:
From Date of Randomization to Measured Progressive Disease or Death Due to Any Cause (Up to 18 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNecitumumab + Nab-Paclitaxel + Carboplatin
Progression Free Survival (PFS)5.59 (4.24 to 7.69)
SecondaryOverall Survival (OS)

OS defined as the time from the date of randomization to the date of death due to any cause. Participants who are alive at the time of study completion or are lost to follow-up will be censored at the time they were last known to be alive.

Time frame:
From Date of Randomization until Death Due to Any Cause (Up to 18 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsNecitumumab + Nab-Paclitaxel + Carboplatin
Overall Survival (OS)15.54 (10.18 to NA)
SecondaryPercentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
From Date of Randomization to Objective Disease Progression or Start of New Anticancer Therapy (Up to 18 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])
percentage of participantsNecitumumab + Nab-Paclitaxel + Carboplatin
Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])78.4
SecondaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin

The Cmin is the minimum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.

Time frame:
Cycle 3 and cycle 4: predose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin
nanogram per milliliter (ng/mL)NecitumumabCarboplatinPaclitaxel
Cycle 365.2 ± 86.90.131 ± 3633.6 ± 393
Cycle 490 ± 74.90.209 ± 197107 ± 313
SecondaryPK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin

The Cmax is the maximum observed serum/plasma concentration of Necitumumab, Nab-Paclitaxel, and Carboplatin.

Time frame:
Cycle 1, 3 and 4: predose and <15minutes (min) post end-of-infusion
Reported as:
Geometric mean · ng/mL
PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin
ng/mLNecitumumabCarboplatinPaclitaxel
Cycle 1231 ± 27.116.4 ± 22343 ± 81.2
Cycle 3291 ± 46.516 ± 26.4284 ± 73
Cycle 4277 ± 42.510.5 ± 160221 ± 77.6
SecondaryImmunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab

A participant was considered to have an anti-drug antibody response if anti-drug antibodies (ADA) were detected at any time point.

Time frame:
Predose Cycle 1 Through Short Term Follow Up (Up To 18 Months)
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab
ParticipantsNecitumumab + Nab-Paclitaxel + Carboplatin
Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab3

Adverse events

Collected over Baseline Up to 49 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Necitumumab + Nab-paclitaxel + Carboplatin: Induction Phase3/54 (5.6%)18/54 (33.3%)54/54 (100%)
Necitumumab + Nab-paclitaxel: Maintenance Phase1/34 (2.9%)5/34 (14.7%)31/34 (91.2%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventNecitumumab + Nab-paclitaxel + Carboplatin: Induction PhaseNecitumumab + Nab-paclitaxel: Maintenance Phase
DiarrhoeaGastrointestinal disorders2/540/34
NauseaGastrointestinal disorders2/540/34
FatigueGeneral disorders2/541/34
Respiratory tract infectionInfections and infestations2/540/34
Neutrophil count decreasedInvestigations2/540/34
Myocardial infarctionCardiac disorders0/541/34
DeathGeneral disorders0/541/34
PneumoniaInfections and infestations0/541/34
FallInjury, poisoning and procedural complications1/541/34
Femur fractureInjury, poisoning and procedural complications1/541/34
Most frequent other events
Showing 10 of 64
Most frequent other events
EventNecitumumab + Nab-paclitaxel + Carboplatin: Induction PhaseNecitumumab + Nab-paclitaxel: Maintenance Phase
AnaemiaBlood and lymphatic system disorders34/5415/34
FatigueGeneral disorders32/546/34
Neutrophil count decreasedInvestigations32/541/34
HypomagnesaemiaMetabolism and nutrition disorders26/547/34
RashSkin and subcutaneous tissue disorders20/546/34
DiarrhoeaGastrointestinal disorders19/544/34
ConstipationGastrointestinal disorders18/542/34
Platelet count decreasedInvestigations17/542/34
NauseaGastrointestinal disorders16/542/34
Dermatitis acneiformSkin and subcutaneous tissue disorders16/544/34

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Necitumumab + Nab-Paclitaxel + Carboplatin
Mean65.96 ± 7.48
Sex: Female, Male
Sex: Female, Male(Participants)Necitumumab + Nab-Paclitaxel + Carboplatin
Female12
Male42
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Necitumumab + Nab-Paclitaxel + Carboplatin
Hispanic or Latino4
Not Hispanic or Latino50
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Necitumumab + Nab-Paclitaxel + Carboplatin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White53
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Necitumumab + Nab-Paclitaxel + Carboplatin
United States15
Germany4
Spain27
Greece8
08

Study locations

1 site
  • Florida Hospital Cancer Institute
    Orlando, Florida 32804, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jan 2018, 27 months.

Results were first posted in Feb 2019, 1 year after primary completion.

Of 83 phase 2 interventional studies under Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 88. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2015
First posted
Mar 19, 2015
StartActual
Oct 12, 2015
Primary completionActual
Jan 29, 2018
CompletionActual
Nov 6, 2019
Results first posted
Feb 12, 2019
Last update
Nov 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02392507
Collaborators
Celgene
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
Oct 12, 2015
Primary completion
Jan 29, 2018
Completion
Nov 6, 2019
Results posted
Feb 12, 2019
Last update
Nov 19, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Necitumumab · Albumin-Bound Paclitaxel · Carboplatin

Start the discussion